BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two oral presentations and three posters on new acoramidis data in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the European Society of Cardiology (ESC) Congress 2026, taking place in Munich, Germany on August 28-31, 2026. The data will further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
Covered in this story
What has happened since
- Bridgebio Pharma Inc is down 16.0% since this was published, 59 days ago.
- Palo Alto Networks is up 1.1% since this was published, 59 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Bridgebio Pharma Inc
- Jefferies: $66.1 → $110 by Oct 2027 · Buy via Investing.com
- TD Cowen: $66.1 → $110 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BBIO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Bridgebio Pharma Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.